Cabaletta Bio Inc

CABA

2.395USD

-0.085-3.43%

Market hours （ET）Quotes delayed by 15 min

Cabaletta Bio Inc's Score

Industry at a Glance

Industry Ranking

224 / 501

Overall Ranking

397 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

12.250

Target Price

+369.35%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Cabaletta Bio Inc Highlights

StrengthsRisks

Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -1.04, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 72.98M shares, increasing 16.59% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 84.83K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.13.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 7.70, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -1.04, which is -60.27% below the recent high of -0.41 and -1380.94% above the recent low of -15.36.

Score

Industry at a Glance

Previous score

7.70

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 224/501

No Data

The company’s current earnings forecast score is 8.40, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Cabaletta Bio Inc is 14.50, with a high of 22.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.40

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.71, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 3.34 and the support level at 2.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.93

Change

0.78

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 79.79%, representing a quarter-over-quarter increase of 58.35%. The largest institutional shareholder is The Vanguard, holding a total of 3.45M shares, representing 3.77% of shares outstanding, with 35.70% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Bain Capital Life Sciences Investors, LLC

9.68M

+250.51%

Adage Capital Management, L.P.

8.83M

+142.94%

Jennison Associates LLC

6.02M

+147.36%

T. Rowe Price Investment Management, Inc.

6.79M

+71.13%

Cormorant Asset Management, LP

5.00M

--

Alyeska Investment Group, L.P.

4.80M

--

The Vanguard Group, Inc.

Star Investors

3.45M

+21.32%

Heights Capital Management, Inc.

3.14M

--

T. Rowe Price Associates, Inc.

Star Investors

2.17M

+376.17%

Jefferies LLC

2.00M

--



1

2



There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 3.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Cabaletta Bio Inc

CABA

4.88 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

MDGL

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Dynavax Technologies Corp

DVAX

8.41 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment